Pre-Open Stock Movers 01/19: (ACRS) (GEVO) (GM) Higher; (PRPH) (EDIT) (MGI) Lower (more...)

Pre-Open Stock Movers:

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) 128.4% HIGHER; announced positive preliminary topline results from a 12-week, Phase 2a, multicenter, randomized, investigator and patient-blind, sponsor-unblinded, parallel group, placebo-controlled clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA) (ATI-450-RA-201). ATI-450 was developed internally utilizing Aclaris proprietary KINect drug discovery platform.

Gritstone Oncology, Inc. (NASDAQ: GRTS) 46.2% HIGHER; today announced that it is advancing development of a second generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged protection and potency against Spike mutants. Gritstone and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have entered into a clinical trial agreement to initiate clinical testing. A Phase 1 clinical trial, expected to be conducted through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), is in development. The Bill & Melinda Gates Foundation (Gates Foundation) is supporting the preclinical evaluation of the vaccine.

Minerva Neurosciences, Inc. (Nasdaq: NERV) 40% HIGHER; Minerva Neuroscience and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will acquire Minervas royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in additional milestone payments. The additional payments to Minerva will be contingent on the achievement of certain clinical, regulatory and commercialization milestones.

Gevo, Inc. (NASDAQ: GEVO) 33% HIGHER; announced today that Frances H. Arnold, a Nobel-Prize recipient and Gevos Co-Founder, has been named to President-Elect Joe Bidens Science Team. The Science Team is tasked with marshaling the force of science to drive meaningful progress in the lives of people. The Science Team will help the Biden-Harris administration confront some of the biggest crises and challenges of our time, including climate change.

TransEnterix, Inc. (NYSE: TRXC) 30.8% HIGHER; announced the Company received CE Mark approval for the Intelligent Surgical UnitTM (ISUTM) that enables machine vision capabilities on the Senhance Surgical System. This approval will provide Senhance digital laparoscopic programs in Europe access to this new technology, ushering them to the forefront of surgical innovation utilizing augmented intelligence.

Ceragon Networks (NASDAQ: CRNT) 26% HIGHER; Extends Surge as Wood's ARK Adds to Holdings - Bloomberg

ProPhase Labs, Inc. (NASDAQ: PRPH) 20.6% LOWER; announced today the pricing of an underwritten public offering of 3,000,000 shares of common stock at an offering price of $12.50 per share, for gross proceeds of $37,500,000. In addition, ProPhase has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares to cover over-allotments, if any. All of the shares are being offered by ProPhase.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) 12.9% LOWER; announced that it has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as a symptomatic treatment in mild-to-moderate Alzheimer's disease (AD). Additional secondary and exploratory efficacy analyses and biomarker data including neurofilament light chain (NfL), neurogranin, tau and amyloid are still pending and expected in the coming months. Troriluzole did not statistically differentiate from placebo at 48 weeks on the study's prespecified co-primary endpoints on the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-cog) and the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) in study participants with mild-to-moderate AD. Troriluzole also did not differentiate from placebo on the key secondary measure of hippocampal volume assessed by magnetic resonance imaging (MRI) in the overall population.

General Motors (NYSE: GM) 7.2% HIGHER; Cruise and General Motors (NYSE: GM) on Tuesday announced they have entered a long-term strategic relationship with Microsoft (Nasdaq: MSFT) to accelerate the commercialization of self-driving vehicles. The companies will bring together their software and hardware engineering excellence, cloud computing capabilities, manufacturing know-how and partner ecosystem to transform transportation to create a safer, cleaner and more accessible world for everyone.

Galapagos NV (NASDAQ: GLPG) 6.5% HIGHER; Morgan Stanley analyst Matthew Harrison upgraded to “Overweight” from “Equal-weight” but lowered the price target from $159.00 to $129.00 per share.

Editas Medicine (NASDAQ: EDIT) 3.8% LOWER; Morgan Stanley downgraded from Equalweight to Underweight with a price target of $45.00.

MoneyGram (NASDAQ: MGI) 3.7% LOWER; Set to Open Lower After Walmart (NYSE: WMT) Enters Pact with Western Union (NYSE: WU).

Peloton Interactive (NASDAQ: PTON) 2.7% LOWER; UBS downgraded from Neutral to Sell with a price target of $124.00 (from $115.00).

American Express (NYSE: AXP) 2% HIGHER; JPMorgan upgraded from Underweight to Overweight with a price target of $148.00 (from $105.00).

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• IBM (IBM) PT Lowered to $179 at Morgan Stanley, 'shares are largely fair valued'
• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises